Brief: Aequus And Camargo Complete Pre-Investigational New Drug Submission With FDA For Transdermal Anti-Nausea Program
17/04/2018 14:11
April 17 (Reuters) - Aequus Pharmaceuticals Inc AQS.V :
* AEQUUS AND CAMARGO COMPLETE PRE-INVESTIGATIONAL NEW DRUG
SUBMISSION WITH FDA FOR TRANSDERMAL ANTI-NAUSEA PROGRAM
* AEQUUS - ANTICIPATES FDA FEEDBACK BY END OF APRIL, WHICH
WILL
DEFINE CLINICAL STRATEGY FOR REGULATORY APPROVAL IN U.S. FOR
AQS1303
Source text for Eikon: ID:nGNX5nKqRh
Further company coverage: AQS.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aequus Pharmaceuticals
See all newsBrief: Aequus Pharmaceutical Canada Pauses Sales Of Evolve Intensive Eyedrops, Gel In Canada
Brief: Aequus Announces Financing To Support Launch Of Zimed Preservative Free (Bimatoprost 0.03%) And Board Update
Brief: Aequus Announces Health Canada Notice Of Compliance For Zimed® Preservative Free
Brief: Aequus Announces Sandoz Contract Expiry At Year End And Expected Health Canada Approval For Zimed® Pf (Preservative Free)
Brief: Aequus Resumes Trading On TSX Venture Exchange